secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001558370-25-000291
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports 27% response rate for vilastobart + atezolizumab in MSS CRC Phase 2 trial
--------------------------------------------------------------------------------

- 27% preliminary ORR (3 PRs, 2 confirmed) in MSS CRC patients without liver metastases as of Jan 13, 2025 cutoff.
- Responses accompanied by decreases in CEA and ctDNA levels and clinical symptom improvement.
- Safety: well-tolerated; 5% colitis, low Grade 3/4 irAEs, no treatment-related deaths.
- Heavily pre-treated population: 70% had ≥3 prior lines of therapy.
- Company plans to seek partnerships; expects to report updated Phase 2 data mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025000291/0001558370-25-000291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025000291/xlo-20250121x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer